Read More Pharma Industry News Novartis gains another potential MS growth engine after remibrutinib beats teriflunomide in two Phase III trials Novartis shares surge after remibrutinib wins two Phase III MS trials, opening another potential growth opportunity alongside Kesimpta. bySoujanya RaviSeptember 3, 2026